Company: ANIX
Filing Date: 2025-09-10
Form Type: S-3
Source: 0001493152-25-013010
Chunk: 55

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: S-3
Chunk 55
---
 to Amend Bylaws

The board of directors has the power to adopt, amend or repeal the bylaws. Bylaws adopted by the board of directors may be repealed or changed, and new bylaws made, by the stockholders, and the stockholders may prescribe that any bylaw made by them shall not be altered, amended or repealed by the board of directors.

| S-10 |

Change in Control

Provisions of Delaware law and our certificate of incorporation and bylaws could make the acquisition of our company by means of a tender offer, proxy contest or otherwise, and the removal of incumbent officers and directors, more difficult. These provisions include:

Section 203 of the DGCL, which prohibits a merger with a 15%-or-greater stockholder, such as a party that has completed a successful tender offer, until three years after that party became a 15%-or-greater stockholder;

The authorization in our certificate of incorporation of undesignated preferred stock, which could be issued without stockholder approval in a manner designed to prevent or discourage a takeover; and

Provisions in our bylaws regarding stockholders’ rights to call a special meeting of stockholders limit such rights to stockholders holding together at least a sixty-six and two-thirds percent of the shares of the Company entitled to vote at the meeting, which could make it more difficult for stockholders to wage a proxy contest for control of our board of directors or to vote to repeal any of the anti-takeover provisions contained in our certificate of incorporation and bylaws.

Together, these provisions may make the removal of management more difficult and may discourage transactions that could otherwise involve payment of a premium over prevailing market prices for our common stock.

Market, Symbol and Transfer Agent

Our common stock is listed for trading on the Nasdaq Capital Market under the symbol “ANIX.” The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC.

| S-11 |

<div align='center'>PLAN OF DISTRIBUTION</div>

We entered into the Controlled Equity Offering SMSales Agreement with Cantor on September 9, 2022, under which we may issue and sell from time to time up to $100,000,000 of our common stock through or to Cantor, as agent or principal, pursuant to this prospectus. Sales of our common stock, if any, under the Controlled Equity Offering SMSales Agreement will be made at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415